These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17868472)

  • 41. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open?
    Kou P; Wei S; Xiong F
    Curr Med Chem; 2019; 26(16):2962-2973. PubMed ID: 29600752
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic interventions for autosomal dominant polycystic kidney disease.
    Edelstein CL
    Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Better understanding of ADPKD results in potential new treatment options: ready for the cure?
    Meijer E; de Jong PE; Peters DJ; Gansevoort RT
    J Nephrol; 2008; 21(2):133-8. PubMed ID: 18446706
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
    Perrone RD; Neville J; Chapman AB; Gitomer BY; Miskulin DC; Torres VE; Czerwiec FS; Dennis E; Kisler B; Kopko S; Krasa HB; LeRoy E; Castedo J; Schrier RW; Broadbent S
    Am J Kidney Dis; 2015 Oct; 66(4):583-90. PubMed ID: 26088508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Defective glycolysis and the use of 2-deoxy-D-glucose in polycystic kidney disease: from animal models to humans.
    Magistroni R; Boletta A
    J Nephrol; 2017 Aug; 30(4):511-519. PubMed ID: 28390001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial.
    El-Damanawi R; Lee M; Harris T; Mader LB; Bond S; Pavey H; Sandford RN; Wilkinson IB; Burrows A; Woznowski P; Ben-Shlomo Y; Karet Frankl FE; Hiemstra TF
    BMJ Open; 2018 May; 8(5):e022859. PubMed ID: 29743334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
    Tao Y; Kim J; Schrier RW; Edelstein CL
    J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Absence of mTOR Inhibitor Effect on Hepatic Cyst Growth: A Case Report of a Kidney Transplant Recipient with Autosomal Dominant Polycystic Kidney Disease.
    Friedrich L; Barbey F; Pascual M; Venetz JP
    Case Rep Transplant; 2012; 2012():513025. PubMed ID: 23304619
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Autosomal dominant polycystic kidney disease: time for a change?
    Chapman AB
    J Am Soc Nephrol; 2007 May; 18(5):1399-407. PubMed ID: 17429048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polycystic kidney disease: a 2011 update.
    Steinman TI
    Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):189-94. PubMed ID: 22274800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease.
    Lacquaniti A; Chirico V; Lupica R; Buemi A; Loddo S; Caccamo C; Salis P; Bertani T; Buemi M
    Peptides; 2013 Nov; 49():1-8. PubMed ID: 23973863
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].
    Cornec-Le Gall E; Le Meur Y
    Nephrol Ther; 2014 Nov; 10(6):433-40. PubMed ID: 25086476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview.
    Corradi V; Gastaldon F; Virzì GM; Caprara C; Martino F; Ronco C
    Minerva Med; 2015 Feb; 106(1):53-64. PubMed ID: 25300895
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Berberine slows cell growth in autosomal dominant polycystic kidney disease cells.
    Bonon A; Mangolini A; Pinton P; Del Senno L; Aguiari G
    Biochem Biophys Res Commun; 2013 Nov; 441(3):668-74. PubMed ID: 24184483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials.
    Myint TM; Rangan GK; Webster AC
    Nephrology (Carlton); 2014 Apr; 19(4):217-26. PubMed ID: 24460701
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk factors for progression in ADPKD.
    Alam A
    Curr Opin Nephrol Hypertens; 2015 May; 24(3):290-4. PubMed ID: 25774748
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Do mTOR inhibitors still have a future in ADPKD?
    Perico N; Remuzzi G
    Nat Rev Nephrol; 2010 Dec; 6(12):696-8. PubMed ID: 21109768
    [No Abstract]   [Full Text] [Related]  

  • 59. Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside.
    Kim HJ; Edelstein CL
    Kidney Res Clin Pract; 2012 Sep; 31(3):132-8. PubMed ID: 26894018
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease.
    Baliga MM; Klawitter J; Christians U; Hopp K; Chonchol M; Gitomer BY; Cadnapaphornchai MA; Klawitter J
    Sci Rep; 2021 Mar; 11(1):6629. PubMed ID: 33758231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.